NovAccess Global Inc. logo

NovAccess Global Inc. (XSNX)

Market Closed
12 Dec, 20:00
OTC PINK OTC PINK
OTC PINK OTC PINK Primary
$
0. 00
0
0%
$
12.38K Market Cap
- P/E Ratio
0% Div Yield
0 Volume
0 Eps
$ 0
Previous Close
Day Range
0 0
Year Range
0 0.01
Want to track XSNX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

XSNX closed yesterday higher at $0, an increase of 0% from Thursday's close, completing a monthly increase of 0% or $0. Over the past 12 months, XSNX stock lost -92.31%.
XSNX is not paying dividends to its shareholders.
The last earnings report, released on May 13, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
NovAccess Global Inc. has completed 1 stock splits, with the recent split occurring on Aug 26, 2020.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

XSNX Chart

No Data

NovAccess Global Inc. (XSNX) FAQ

What is the stock price today?

The current price is $0.00.

On which exchange is it traded?

NovAccess Global Inc. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is XSNX.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 12.38K.

Has NovAccess Global Inc. ever had a stock split?

NovAccess Global Inc. had 1 splits and the recent split was on Aug 26, 2020.

NovAccess Global Inc. Profile

Biotechnology Industry
Healthcare Sector
Dr. Dwain K. Morris-Irvin M.P.H., MPH, Ph.D. CEO
OTC PINK Exchange
67001N107 CUSIP
US Country
3 Employees
- Last Dividend
26 Aug 2020 Last Split
- IPO Date

Overview

NovAccess Global Inc. is a pioneering biopharmaceutical enterprise based in Chesterland, Ohio, dedicated to the development of innovative immunotherapies designed to combat brain tumors. Founded in 1997, the company has carved a niche in the medical field by focusing its research efforts on harnessing and enhancing the body's immune system to target and eradicate cancer cells. By concentrating on these novel therapeutic approaches, NovAccess Global Inc. aims to offer new hope and advanced treatment options to patients across the United States suffering from this challenging and often deadly disease.

Products and Services

  • Immunotherapies for Brain Tumors:

    • NovAccess Global Inc. is at the forefront of developing groundbreaking immunotherapies tailored specifically for the treatment of brain tumors. These therapies leverage the power of the patient's immune system, employing it as a natural weapon against cancerous cells. By activating and enhancing specific components of the immune response, these treatments aim to identify and destroy brain tumor cells, offering a personalized and targeted approach to cancer care.

Contact Information

Address: 8834 Mayfield Road
Phone: 440 644 1027
Affiliate Program About Terms Privacy Help Contact Us
2025 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark